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Abstract Carcinomas of the ampulla of Vater are rare and
assumed to generally arise from preexisting adenomas
(adenoma–carcinoma sequence). Histologically, distinct
subtypes can be distinguished that were shown to differ
significantly in terms of clinical outcome. Since patholo-
gists usually receive bioptic tissue samples of ampullary
tumors obtained during endoscopy, accurate classification
of carcinoma subtypes can sometimes be difficult on
morphological criteria alone. We therefore performed
immunohistochemistry using a panel of established marker
proteins (CK7, CK20, p21, p27, ESA, bax, and ephrin-B2)
on 175 carcinoma, 111 adenoma, and 152 normal mucosa
specimens of the ampulla of Vater and identified distinct
immunoprofiles for every carcinoma subtype. Fluorescence
in situ hybridization analyses of therapeutic target genes
(c-myc, EGFR1, CCND1, HER2) found CCND1 to
represent the most frequently amplified gene in our series
(7.5%).
Keywords Ampullary carcinoma . Papilla of Vater . FISH .
TMA . Amplification . CCND1
Introduction
The papilla of Vater is a complex anatomical unit composed
of highly specialized mucosa and musculature and repre-
sents the orifice of the pancreatic and bile duct within the
duodenum. It contains the border between two completely
different types of mucosa (intestinal mucosa of the
duodenum and pancreatico-biliary duct mucosa) and regu-
lates the flow of bile and pancreatic secretions with its
sphincteric muscle (sphincter of Oddi) [1].
Tumors of the ampulla of Vater are rare, with an
incidence of approximately 5.7 cases per million population
per year, but are still more common than tumors of the rest
of the small intestine [2–4]. Among periampullary tumors,
they rank second after tumors of the pancreatic head and
account for 6–20% of cases [5, 6]. In 30–91% of ampullary
carcinomas, residual adenomatous areas are detectable,
indicating an adenoma–carcinoma sequence with stepwise
accumulation of genetic alterations, similar to that observed
in colorectal cancer [7, 8]. Due to the crucial function of the
ampulla of Vater, neoplastic lesions early lead to an
occlusion of the papillary orifice and therefore result in
congestion of bile and pancreatic secretions. Patients
generally present with obstructive jaundice, and histologic
diagnosis can be achieved after biopsy during endoscopic
retrograde cholangiopancreatography [9]. Early detection
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but also biologic differences are thought to be responsible
for the better prognosis of ampullary tumors following
pancreaticoduodenectomy compared to other periampullary
tumors [10–12]. Concerning ampullary carcinomas, several
surgical series have reported a median survival of 30 to
50 months and 5-year survival rates between 21% and 64%
[6, 13–15].
The histopathology of ampullary carcinomas includes a
broad spectrum of distinct subtypes, deriving from the
different types of mucosa adjoining in the papilla of Vater
[3, 5]. According to the classification by the Armed Forces
Institute of Pathology (AFIP), an intestinal type (IT),
resembling carcinomas of intestinal origin, and a pancrea-
tico-biliary type (PBT), resembling carcinomas of the
extrahepatic bile ducts or the pancreas, are the most
common subtypes and account for 70–95% of cases [5, 6,
16–21]. Other subtypes include an intestinal-mucinous type
(IMT), an invasive papillary type (IPT), a poorly differen-
tiated adenocarcinoma (G3AC), and several rather uncom-
mon entities [18]. Interestingly, the distinct subtypes were
shown to differ significantly in cumulative survival, with IT
demonstrating a mean survival of 76 months compared to
41 months in PBT (Ruemmele et al., submitted for
publication). Since classification of ampullary tumors,
particularly in bioptic material, can sometimes be difficult
on histological criteria alone, we investigated 175 carcino-
ma, 111 adenoma, and 152 normal mucosa specimens of
the papilla of Vater for their immunohistochemical expres-
sion of marker proteins commonly altered during carcino-
genesis, including cytokeratins 7 and 20, cell cycle
inhibitors p21 and p27, epithelium-specific intercellular
adhesion molecule [epithelial specific antigen (ESA)],
promoter of apoptosis bax, and regulator of angiogenesis
ephrin-B2, and created immunoprofiles of the distinct
subtypes. Additionally, fluorescence in situ hybridization
(FISH) analyses were performed to determine whether
known oncogenes, that can serve as potential target genes
for current or future gene-specific therapies (c-myc,
EGFR1, CCND1, HER2), participate in genomic rearrange-
ments and could therefore be of clinical significance in
ampullary carcinoma.
Materials and methods
Tissue samples and patient characteristics
The files of the Institute of Pathology, University Hospital
Basel (Switzerland), the Institute of Pathology, University
of Regensburg (Germany), the Institute of Pathology
Nuernberg, and the Anatomic Pathology Unit, Department
of Human Morphology, University of Insubria, Varese
(Italy) were searched for adenomas or carcinomas of the
ampulla of Vater over the period from 1985 to 2005. In
total, 175 carcinoma, 111 adenoma, and 152 normal mucosa
samples were retrieved. Sufficient paraffin-embedded tissue
for tissue microarray (TMA) construction was available in
all cases. The male-to-female ratio was 3:2; mean age at
diagnosis was 63 years (range 15–81 years).
TMA construction
Tissue samples were fixed in buffered 4% formalin,
embedded in paraffin, and used to construct a TMA.
Briefly, hematoxylin–eosin (H&E)-stained sections were
made from each selected primary block (donor blocks) to
define representative tissue regions. Tissue cylinders
(0.6 mm in diameter) were then punched from the region
of the donor block with the use of a custom-made precision
instrument (Beecher Instruments, Silver Spring, USA).
Tissue cylinders were transferred to a 25×35 mm paraffin
block to produce the TMA block used for the study. The
resulting TMA block was cut into 3 μm sections that were
transferred to glass slides by use of the Paraffin Sectioning
Aid System (Instrumedics, Hackensack, USA). Sections
from the TMA block were used for immunohistochemistry.
The number of punches per patient ranged from one to
three for both normal tissue and carcinoma and from one to
five for patients with adenomas. One punch was collected
per patient on average (median 1.0) for each of the tissue
types.
Histology and immunophenotyping
All tissue samples were reviewed by two experienced
surgical pathologists (P.R. and L.M.T.) based exclusively
on H&E staining. Carcinomas were subclassified according
to the criteria published by the AFIP [18]. Tumors
essentially indistinguishable from colorectal carcinomas
were classified as intestinal types, whereas carcinomas
showing a dense desmoplastic stroma surrounding small
glands or solid nests of tumor cells were referred to as the
pancreaticobiliary subtype. Invasive papillary carcinomas
typically formed papillary and micropapillary structures in
their invasive component, and poorly differentiated adeno-
carcinomas lacked histologic features of glandular or other
differentiation. Additionally, an intestinal-mucinous sub-
type, characterized by any mucinous differentiation, was
defined. Characteristics of antibodies are listed in Table 1.
Evaluation of immunohistochemistry
Immunoreactivity for each protein marker was scored semi-
quantitatively by evaluating the number of positive tumor
cells over the total number of tumor cells. Scores were
assigned using 5% intervals and ranged from 0% to 100%.
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The reproducibility of this scoring method between
pathologists has previously been demonstrated for TMAs
[22, 23]. In order to select the cut-off score for protein
marker positivity, receiver operating characteristic curve
(ROC) analysis was performed [24]. Using this method, the
sensitivity and 1-specificity of the protein marker for the
outcome at each protein expression score is plotted, thus
generating the ROC curve. The (0,1 criterion) was used to
identify the point on the curve maximizing the sensitivity
and specificity for the outcome and thereby having the
shortest distance to the coordinate (0,1). The protein
expression score corresponding to this point was thus
selected as the threshold value above which a tumor was
considered “positive”.
Fluorescence in situ hybridization
Five-micrometer sections of the TMA were made and
treated according to the paraffin pretreatment reagent kit
protocol before hybridization (Vysis, IL, USA). Spectru-
mOrange-labelled gene-specific probes were used together
with SpectrumGreen-labelled probes for the respective
centromere as a reference. The probe combinations were:
c-myc/centromere 8 (Vysis), EGFR1/centromere, 7 (Vysis)
CCND1/centromere 11 (Vysis), and HER2/centromere 17
(Vysis). Hybridization was performed according to the
manufacturer’s instructions (Vysis). Tumors were consid-
ered amplified if the ratio between oncogene and
corresponding centromere was >2.0. Polysomy on the other
hand was defined as more than two oncogene and
centromere copies per nucleus without an increase in the
ratio between oncogene and corresponding centromere.
Statistical analyses
Differences in negative and positive expression between
tumor types were evaluated by the chi-square test. The
predictive and independent value of the immunohistochem-
ical markers to discriminate between tumor types was
carried out by univariate and multiple logistic regression
analysis. The odds ratio (OR), 95%CI, and p values were
used to determine the effect of each marker on outcome. All
analyses were carried out using SAS V9 (The SAS
Institute, Cary, NC, USA), and p values <0.05 were
considered statistically significant.
Results
Histologic classification of ampullary carcinomas
Classification of 175 ampullary carcinomas investigated in
our series identified 85 intestinal types, 42 pancreatico-
biliary types, 23 poorly differentiated adenocarcinomas, 16
intestinal-mucinous types, and nine invasive papillary types
(Fig. 1).
Grading of adenomas and association to carcinoma
subtypes
Histologic grading was evaluable in 76 of 111 (68%)
adenomas of our series and disclosed low-grade dysplasia
in 57 of 76 (75%) and high-grade dysplasia in 19 of 76
(25%) cases. All adenomas demonstrated tubular or
tubulovillous architecture. Seventy-eight of 111 (70%)
adenoma samples were derived from patients suffering
from coexisting carcinoma. The corresponding subtypes
were 49 IT, 13 IMT, 8 PBT, 6 G3AC, and 2 IPT.
Immunophenotyping of ampullary carcinomas, adenomas,
and normal mucosa
The immunoprofiles of all investigated carcinoma, adeno-
ma, and normal mucosa samples are shown in Table 2 and
Fig. 2, respectively. The most discriminating results were
demonstrated for CK7 and bax. Whereas normal, pre-
malignant and malignant tissue samples stained increasing-
ly positive for CK7 (2.6%, 12.8%, and 44.7%), bax
revealed an opposite trend (55.6%, 64.3%, and 37.6%).
Additionally, p21 and p27 showed significant differences in
their expression values between the three groups.
Immunophenotyping of ampullary carcinoma subtypes
Of the eight immunohistochemical marker proteins inves-
tigated, CK7 (p<0.001), p27 (p=0.012), ESA (p=0.038),
and bax (p<0.001) expression demonstrated significant
differences among the tumor types (Table 3 and Fig. 3).
More than 75% of PBT and 72.2% of G3AC showed no
expression of bax, while 92.3% of IMT were negative for
CK7. IT stained negative for CK7 in 67.5% of cases and
were never positive for CK7, p27, and ESA and negative
Table 1 Characteristics of antibodies
Antibody Dilution Detection Manufacturer
CK7 1:200 Bond Dako Cytomation
CK20 1:50 Bond Dako Cytomation
p21 1:25 Bond Dako Cytomation
p27 1:200 Bond Dako Cytomation
ESA 1:200 Bond Novocastra
bax 1:100 Bond Neomarkers
ephrin-B2 1:200 ABC R&D Systems
ESA epithelial specific antigen, Bond Bond Vision Biosystems, ABC
avidin–biotin–peroxidase-complex
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for bax simultaneously. The association of p27, ESA,
bax, and CK7 were evaluated in univariate and multi-
variable analysis in order to establish immunophenotypes
specific for each tumor subtype. Findings are summa-
rized in Fig. 4.
CK7 negativity [p=0.002; OR=0.37 (0.2–0.7)] and
positivity of bax [p=0.003; OR=2.76 (0.4–5.4)], p27 [p=
0.044; OR=2.0 (1.2–4.2)] and ESA [p=0.012; OR=2.3
(1.2–4.2)] were significantly associated with the IT tumor
type. Multivariable analysis demonstrated, however, that
Fig. 1 Gross findings of an ampullary carcinoma showing a sessile exophytic tumor at the ampullary orifice (a). Histologic findings of ampullary
carcinoma subtypes: IT (b), PBT (c), IMT (d), IPT (e), and G3AC (f) (H&E ×400)
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only CK7 (p<0.001) and bax (p<0.001) were independent
predictors of this phenotype and useful in the discrimination
of IT from other tumors (sensitivity 0.69, specificity 0.58).
In contrast, CK7 positivity [p<0.001; OR=5.03 (2.2–
11.3)] and absence of bax [p<0.001; OR=0.22 (0.1–0.5)],
p27 [p=0.001; OR=0.22 (0.1–0.6)], and ESA [p=0.004;
OR=0.31 (0.1–0.7)] were significantly associated with the
PBT tumor type compared to the remaining subtypes. CK7,
bax, and p27 were independently predictive (p<0.001) of
PBT (sensitivity 0.92, specificity 0.48).
The discrimination of IMT tumors could be best
performed by assessing CK7. Absence of CK7 [p=0.023;
OR=0.09 (0.01–0.7)] expression was very strongly predic-
tive of IMT and was the only marker found to discriminate
IMT from the remaining tumor types (sensitivity 0.87,
specificity 0.65).
None of the immunohistochemical markers were signif-
icantly predictive of either G3AC or IPT.
FISH analyses
The results of the FISH analyses are presented in Table 4.
The number of evaluable cases varied between different
FISH probes due to insufficient hybridization, absence of
unequivocal tumor cells in the arrayed tissue, as well as
lack of tissue on serial sections of the array. CCND1
showed the highest amplification frequency among the
analyzed genes (two of 74 adenomas and ten of 134
carcinomas) in our series, whereas c-myc, EGFR, and
HER2 were amplified only infrequently. There were no
associations between gene amplifications and distinct
histologic subtypes of ampullary carcinomas.
Table 2 Immunoprofiles of normal mucosa, adenoma, and carcinoma tissue samples




Negative 113 (97.4) 82 (87.2) 89 (55.3)
<0.001*
Positive 3 (2.6) 12 (12.8) 72 (44.7)
CK20 50
Negative 58 (46.4) 52 (53.6) 76 (47.5)
0.524
Positive 67 (53.6) 45 (46.4) 84 (52.5)
p21 0
Negative 90 (74.4) 61 (62.9) 96 (59.6)
0.031**
Positive 31 (25.6) 36 (37.1) 65 (40.4)
p27 5
Negative 39 (32.5) 33 (35.5) 75 (52.8)
0.002***
Positive 81 (67.5) 60 (64.5) 67 (47.2)
ESA 90
Negative 63 (50.4) 51 (52.0) 78 (48.7)
0.874
Positive 62 (49.6) 47 (48.0) 82 (51.3)
bax 10
Negative 51 (44.4) 30 (35.7) 93 (62.4)
<0.001****
Positive 64 (55.6) 54 (64.3) 56 (37.6)
ephB2 75
Negative 76 (65.5) 48 (62.3) 72 (51.4)
0.058
Positive 40 (34.5) 29 (37.7) 68 (48.6)
*Significant difference between normal and adenoma (p<0.001) and normal and carcinoma (p<0.001)
**Significant difference between normal and carcinoma (p=0.01)
***Significant difference between normal and carcinoma (p=0.001) and adenoma and carcinoma (p=0.009)
****Significant difference between normal and carcinoma (p=0.004) and adenoma and carcinoma (p<0.001)
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Discussion
Carcinomas of the small intestine represent only 1% of all
gastrointestinal malignant tumors but are most common
around the papilla of Vater [25–28]. There is good evidence
for an adenoma–carcinoma sequence since ampullary
carcinomas demonstrate residual adenomatous areas in up
to 84% of cases [29–31]. On the other hand, up to 65% of
Fig. 2 CK7/bax immunostaining in normal mucosa (a, d), adenoma (b, e), and carcinoma (c, f) (×400)
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patients suffering from adenoma were shown to have
coexisting carcinoma [32]. Ampullary carcinomas are
heterogeneous in terms of their histomorphological differ-
entiation, probably due to the distinct epithelial subtypes
adjoining in the ampulla of Vater [16–18]. In our series, IT
(85 of 175, 49%) and PBT (42 of 175, 24%) were the most
common subtypes, followed by G3AC (23 of 175, 13%),
IMT (16 of 175, 9%), and IPT (nine of 175, 5%). This is in
line with most of the reported series in the literature with
only some smaller studies demonstrating PBT to be more
common than IT [5, 6, 16–18, 20, 21]. Importantly, the
distinct histologic subtypes were shown to exhibit signifi-
cant differences in clinical outcome, with IT and IMT
demonstrating a favorable prognosis [cumulative survival
(CS) 97 and 76 months] compared to IPT, PBT, and G3AC
(CS 59, 41, and 19 months; Ruemmele et al., submitted for
publication). The favorable prognosis of IT compared to
PBT has previously been shown in several studies [16, 17,
20]. During staging procedures in patients with ampullary
tumors, pathologists generally receive endoscopically
obtained biopsies that can be difficult to interpret and to
classify on histomorphological criteria alone. Our study
therefore aimed to delineate immunohistochemical and
genomic profiles of the distinct carcinoma subtypes using
FISH analyses and an immunohistochemical panel of
common marker proteins.
Carcinoma, adenoma, and normal ampullary mucosa
samples demonstrated statistically significant differences in
the expression of CK7 and bax. Whereas CK7 expression
increased from normal to malignant tissue samples, bax
expression decreased in the same manner. The remaining
protein markers, particularly p27, also revealed significant
differences in their expression values between the three
groups but not as unequivocally as CK7 and bax.
Concerning the histologic subtypes of ampullary carcino-
mas, the expression levels of CK7, p27, ESA, and bax
demonstrated the most distinctive results. Whereas more
than 75% of PBT and 72.2% of G3AC were negative for
bax, IMT was negative for CK7 in 92% of cases.
Accordingly, multivariable analysis showed lack of CK7
Table 3 Immunoprofiles of carcinoma subtypes
Protein Expression Cutoff Histologic type (N=175) p value
IT N=85 IMT N=16 PBT N=42 G3AC N=23 IPT N=9
CK7 80
Negative 54 (67.5) 12 (92.3) 10 (26.3) 10 (47.6) 3 (33.3)
<0.001
Positive 26 (32.5) 1 (7.7) 28 (73.7) 11 (52.4) 6 (66.7)
CK20 50
Negative 33 (41.8) 7 (50.0) 19 (51.3) 11 (52.4) 6 (66.7)
0.588
Positive 46 (58.2) 7 (50.0) 18 (48.7) 10 (47.6) 3 (33.3)
p21 0
Negative 41 (52.6) 7 (50.0) 28 (71.7) 14 (66.7) 6 (66.7)
0.27
Positive 37 (47.4) 7 (50.0) 11 (28.3) 7 (33.3) 3 (33.3)
p27 5
Negative 32 (44.4) 5 (45.5) 26 (78.8) 7 (38.9) 5 (62.5)
0.012
Positive 40 (55.6) 6 (54.6) 7 (21.2) 11 (61.1) 3 (37.5)
ESA 90
Negative 31 (38.7) 7 (50.0) 26 (70.3) 10 (50.0) 4 (44.4)
0.038
Positive 49 (61.3) 7 (50.0) 11 (19.7) 10 (50.0) 5 (55.6)
bax 10
Negative 29 (39.2) 3 (25.0) 28 (77.8) 13 (72.2) 4 (44.4)
<0.001
Positive 45 (60.8) 9 (75.0) 8 (22.2) 5 (27.8) 5 (55.6)
ephB2 75
Negative 36 (50.0) 9 (75.0) 15 (46.9) 7 (46.7) 5 (55.6)
0.526
Positive 36 (50.0) 3 (25.0) 17 (53.1) 8 (53.3) 4 (44.4)
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to be strongly predictive for IMT, whereas CK7 positivity
and negativity for bax, p27, and ESA were significantly
associated with PBT. Expression of CK7 was rather
uncommon in IT (32.5%). Multivariable analysis consis-
tently demonstrated CK7 negativity and positivity for p27,
ESA, and bax to be strongly correlated with IT. IPT
represented the rarest subtype in our series, and therefore,
only limited conclusions can be drawn concerning a
Fig. 3 Immunostaining of CK7 in IT (a), bax in IT (b), CK7 in PBT (c), bax in PBT (d), CK7 in IMT (e), and bax in G3AC (f) (×400)
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representative immunoprofile. Nevertheless, IPT tended to
stain positive for CK7 and negative for p27 in most of the
investigated cases.
FISH analyses demonstrated amplification of c-myc,
EGFR1, CCND1, and HER2 only infrequently with no
obvious correlations to carcinoma subtypes. From all
investigated oncogenes, CCND1 showed the highest am-
plification frequency in our series (two of 74 adenomas and
ten of 134 carcinomas). The CCND1 gene is coding for a
cyclin which is known to be translocated, amplified, and
overexpressed in many different tumor types including
mantle cell lymphoma, head and neck carcinoma, breast
carcinoma, hepatocellular carcinoma, gastrointestinal stro-
mal tumors, and various sarcomas [33–36]. Since CCND1
has been shown to be essential for malignant transformation
of epithelial cells, it could play an important role in
tumorigenesis in a distinct subset of ampullary carcinomas.
C-myc, that we demonstrated only recently to be amplified
in up to 14.2% of colorectal carcinomas, showed no
amplification in any of the ampullary carcinomas investi-
gated [37]. Whereas EGFR was only amplified in one case,
HER2 showed amplification in 6% of adenomas and
carcinomas (two IT, two IPT, one G3AC). A small fraction
of patients with ampullary carcinomas could therefore be
candidates for a targeted therapy with Herceptin.
Taken together, accurate classification of ampullary
carcinomas is of crucial importance since the distinct
Fig. 4 Flow chart demonstrating immunoprofiles of carcinoma subtypes
Table 4 Amplification of oncogenes
Oncogene Amplification
Normal Adenoma Carcinoma
c-myc N=26 N=36 N=70
0/26 1/36 0/70
EGFR N=83 N=79 N=137
0/83 1/79 1/137a
CCND1 N=88 N=74 N=134
0/88 2/74 10/134b
HER2 N=46 N=45 N=82
0/46 3/45 5/82c
a One IT
b Six IT, two PBT, one G3AC, one IPT
c Two IT, one G3AC, two IPT
Virchows Arch (2008) 453:579–588 587
subtypes were shown to differ significantly in clinical
outcome. Using an immunohistochemical panel of estab-
lished marker proteins including CK7, p27, ESA, and bax
can improve and facilitate differential diagnosis, especially
in small and fragmented biopsy samples. A subset of
ampullary tumors, furthermore, shows amplification of
CCND1 and HER2 which could represent potential targets
for cancer therapy. The large number of tumors included in
this study highlights the presence of rare molecular events
that can be of potential therapeutic relevance.
Conflict of interest statement We declare that we have no conflict
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